Baxter International Inc.
NYSE:BAXMedical - Instruments & Supplies
-$1.07 today
- Market cap
- $13.53B
- Beta
- 0.64
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.13
- Dividend yield
- 1.03%
Volume 4.01M
Average 7.62M
BAX Total Current Liabilities
All obligations due within one year.
Baxter International Inc.NYSE: BAX
Total Current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total current liabilities rises 22.2% from a year ago
Total current liabilities stood at $3.59B at the end of Q2 FY2026, up 22.2% from a year earlier and down 2.8% from the prior quarter. Over 3 fiscal years it compounded at -14.5% a year.
Context
- Total current liabilities amounted to 18.1% of total assets at the end of Q2 FY2026, up 4.2 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +22.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 2.97B USD
- Year-over-year change
- -54.4%
- 4-year CAGR
- -8.5%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.97B | -54.4% |
| FY2024 | 2024-12-31 | 6.51B | +0.1% |
| FY2023 | 2023-12-31 | 6.5B | +37.0% |
| FY2022 | 2022-12-31 | 4.75B | +12.0% |
| FY2021 | 2021-12-31 | 4.24B | — |
Total Current Liabilities vs competitors
How BAX compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +22.2% is the 2nd highest of 5, against a peer median of +5.3%.
- Total current liabilities amounts to 18.1% of total assets for BAX, versus a peer median of 16.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | €7.18B EUR | +26.8% | -1.2% | 22.9% | |
| Jun 2026 | $3.59B USD | +22.2% | -14.5% | 18.1% | |
| Jun 2026 | $2.86B USD | -2.7% | +6.2% | 16.1% | |
| Jun 2026 | $498.36M USD | +3.2% | +0.3% | 12.5% | |
| Mar 2026 | $17.14M USD | +7.3% | +11.7% | 17.4% | |
| Peer median (excluding BAX) | — | +5.3% | +3.3% | 16.7% | |
Competitors are the stored peer set for BAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2.95B | 1.72B | 3.08B | 1.76B | 1.97B |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 2.71B | 2.62B | 1.77B | 1.73B | 1.93B |
| Inventory | 2.45B | 2.68B | 1.92B | 2.05B | 2.23B |
| Other Current Assets | 390M | 618M | 2.51B | 2.95B | 479M |
| Total Current Assets | 8.87B | 8.01B | 9.6B | 8.85B | 6.87B |
| Property, Plant & Equipment (Net) | 5.81B | 5.24B | 3.21B | 3.18B | 3.19B |
| Goodwill | 9.84B | 6.45B | 5.79B | 5.28B | 4.93B |
| Intangible Assets | 7.79B | 6.79B | 5.92B | 5.22B | 4.37B |
| Long-term Investments | 195M | 247M | 136M | 109M | 103M |
| Tax Assets | 376M | 280M | 263M | 204M | 0 |
| Other Non-current Assets | 642M | 1.27B | 3.36B | 2.94B | 596M |
| Total Non-current Assets | 24.65B | 20.28B | 18.68B | 16.93B | 13.18B |
| Total Assets | 33.52B | 28.29B | 28.28B | 25.78B | 20.06B |
| Account Payables | 1.25B | 1.11B | 881M | 968M | 999M |
| Short-term Debt | 511M | 1.4B | 2.67B | 2.75B | 84M |
| Tax Payables | 264M | 254M | 268M | 217M | 0 |
| Deferred Revenue | 162M | 154M | 128M | 131M | 141M |
| Other Current Liabilities | 751M | 618M | 1.64B | 1.53B | 1.22B |
| Total Current Liabilities | 4.24B | 4.75B | 6.5B | 6.51B | 2.97B |
| Long-term Debt | 17.15B | 15.23B | 11.09B | 10.37B | 9.68B |
| Deferred Tax Liabilities | 962M | 661M | 403M | 103M | 245M |
| Deferred Revenue (Non-current) | 84M | 40M | 41M | 40M | 36M |
| Other Non-current Liabilities | 1.45B | 1.27B | 1.51B | 1.49B | 783M |
| Total Non-current Liabilities | 20.16B | 17.65B | 13.31B | 12.25B | 10.98B |
| Total Liabilities | 24.4B | 22.39B | 19.81B | 18.76B | 13.95B |
| Common Stock | 683M | 683M | 683M | 683M | 683M |
| Retained Earnings | 17.07B | 14.05B | 16.11B | 14.93B | 13.71B |
| Accumulated OCI | (3.38B) | (3.83B) | (3.55B) | (4.01B) | (3.75B) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 44M | 62M | 66M | 60M | (27M) |
| Total Equity | 9.12B | 5.9B | 8.47B | 7.02B | 6.1B |
| Total Debt | 18.31B | 17.2B | 14.11B | 13.45B | 10B |
| Net Debt | 15.36B | 15.49B | 11.04B | 11.69B | 8.04B |
Baxter International Inc.
NYSE:BAX
Intrinsic Alpha fair value
Locked
Current Price
$26.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.